We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Available until 3/1/2021

Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.

Already Have An Account? Log in Now

story of the week

Journal Scan / Research · January 12, 2021

Osteonecrosis of the Jaw Associated With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer

JAMA Oncology




This abstract is available on the publisher's site.

Access this abstract now

Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Oncology
Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer
JAMA Oncol 2020 Dec 17;[EPub Ahead of Print], CH Van Poznak, JM Unger, AK Darke, C Moinpour, RA Bagramian, MM Schubert, LK Hansen, JD Floyd, SR Dakhil, DL Lew, JL Wade, MJ Fisch, NL Henry, DL Hershman, J Gralow

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.

Further Reading